PTX3 is a prototypic soluble pattern recognition receptor, expressed at sites of inflammation and involved in regulation of the tissue homeostasis. PTX3 systemic levels increase in many (but not all) immune-mediated inflammatory conditions. Research on PTX3 as a biomarker has so far focused on single diseases. Here, we performed a multi-group comparative study with the aim of identifying clinical and pathophysiological phenotypes associated with PTX3 release. PTX3 concentration was measured by ELISA in the plasma of 366 subjects, including 96 patients with giant cell arteritis (GCA), 42 with Takayasu’s arteritis (TA), 10 with polymyalgia rheumatica (PMR), 63 with ANCA-associated systemic small vessel vasculitides (AAV), 55 with systemic lupus erythematosus (SLE), 21 with rheumatoid arthritis (RA) and 79 healthy controls (HC). Patients with SLE, AAV, TA and GCA, but not patients with RA and PMR, had higher PTX3 levels than HC. PTX3 concentration correlated with disease activity, acute phase reactants and prednisone dose. It was higher in females, in patients with recent-onset disease and in those with previous or current active vasculitis at univariate analysis. Active small- or large- vessel vasculitis were the main independent variables influencing PTX3 levels at multivariate analysis. High levels of PTX3 in the blood can contribute to identify an increased risk of vascular involvement in patients with systemic immune-mediated diseases.

PTX3 intercepts vascular inflammation in systemic immune-mediated diseases / Ramirez, G. A.; Rovere-Querini, P.; Blasi, M.; Sartorelli, S.; Di Chio, M. C.; Baldini, M.; De Lorenzo, R.; Bozzolo, E. P.; Leone, R.; Mantovani, A.; Manfredi, A. A.; Tombetti, E.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 10:(2019), p. 1135. [10.3389/fimmu.2019.01135]

PTX3 intercepts vascular inflammation in systemic immune-mediated diseases

Ramirez G. A.;Rovere-Querini P.;De Lorenzo R.;Leone R.;Manfredi A. A.;
2019-01-01

Abstract

PTX3 is a prototypic soluble pattern recognition receptor, expressed at sites of inflammation and involved in regulation of the tissue homeostasis. PTX3 systemic levels increase in many (but not all) immune-mediated inflammatory conditions. Research on PTX3 as a biomarker has so far focused on single diseases. Here, we performed a multi-group comparative study with the aim of identifying clinical and pathophysiological phenotypes associated with PTX3 release. PTX3 concentration was measured by ELISA in the plasma of 366 subjects, including 96 patients with giant cell arteritis (GCA), 42 with Takayasu’s arteritis (TA), 10 with polymyalgia rheumatica (PMR), 63 with ANCA-associated systemic small vessel vasculitides (AAV), 55 with systemic lupus erythematosus (SLE), 21 with rheumatoid arthritis (RA) and 79 healthy controls (HC). Patients with SLE, AAV, TA and GCA, but not patients with RA and PMR, had higher PTX3 levels than HC. PTX3 concentration correlated with disease activity, acute phase reactants and prednisone dose. It was higher in females, in patients with recent-onset disease and in those with previous or current active vasculitis at univariate analysis. Active small- or large- vessel vasculitis were the main independent variables influencing PTX3 levels at multivariate analysis. High levels of PTX3 in the blood can contribute to identify an increased risk of vascular involvement in patients with systemic immune-mediated diseases.
2019
ANCA associated small vessel vasculitis
Autoimmunity
Giant cell arteritis
Intravascular immunity
Lupus
PTX3
Rheumatoid arthritis
Takayasu arteritis
Acute-Phase Proteins
Adult
Aged
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Arthritis, Rheumatoid
Autoimmune Diseases
Biomarkers
C-Reactive Protein
Case-Control Studies
Female
Giant Cell Arteritis
Granulomatosis with Polyangiitis
Humans
Inflammation
Lupus Erythematosus, Systemic
Male
Middle Aged
Prednisone
Serum Amyloid P-Component
Takayasu Arteritis
Vasculitis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/102270
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 32
social impact